摘要
目的:研究非小细胞肺癌(NSCLC)中miR-29a-3p的表达及其对肿瘤细胞增殖和迁移的影响。方法:选取12例手术切除的NSCLC组织标本及NSCLC细胞株H1299和A549,采用实时荧光定量聚合酶链反应(RT-qPCR)检测NSCLC组织及细胞株中miR-29a-3p的表达。通过转染H1299和A549过表达miR-29a-3p,采用CCK-8和EDU实验检测miR-29a-3p过表达对NSCLC细胞增殖的影响,划痕实验检测miR-29a-3p过表达对NSCLC细胞迁移的影响。通过miRDB、RNA22、TarBase和TargetScan数据库预测miR-29a-3p靶基因,Gene Ontology(GO)富集分析探究miR-29a-3p可能的生物学通路。结果:NSCLC组织和细胞中miR-29a-3p表达水平明显降低,过表达miR-29a-3p能抑制NSCLC细胞增殖和迁移。miR-29a-3p靶基因GO富集分析显示miR-29a-3p主要与细胞外基质结构成分、内质网腔、多肽赖氨酸修饰等通路密切相关。结论:NSCLC中miR-29a-3p显著低表达,miR-29a-3p能抑制NSCLC细胞的增殖和迁移。
Objective:To investigate the expression of miR-29a-3p in non‐small cell lung cancer(NSCLC)and its role in the proliferation and migration of NSCLC.Methods:Real-time fluorescence quantitative polymerase chain reaction(RT-qPCR)was used to detect the expression of miR-29a-3p in NSCLC tissues,H1299 and A549 cells.NSCLC cell lines H1299 and A549 overexpressed miR-29a-3p.CCK-8 and EDU experiments were used to analyze the effect of miR-29a-3p overexpression on the proliferation of NSCLC cells,scratch assay was used to analyze the effect of miR-29a-3p overexpression on the migration of NSCLC cells.Databases of miRDB,RNA22,TarBase and TargetScan predicted the target genes of miR-29a-3p,and Gene Ontology(GO)enrichment analysis was conducted to explore the possible biological mechanism of miR-29a-3p.Results:The expression level of miR-29a-3p was significantly decreased in NSCLC tissues and cells.CCK8 and EDU experiments indicated that overexpression of miR-29a-3p could effectively inhibit the proliferation of NSCLC cells,and scratch assay indicated that overexpression of miR-29a-3p significantly inhibited the migration of NSCLC cells.GO enrichment analysis of miR-29a-3p target genes revealed that miR-29a-3p was closely related to extracellular matrix structural components,endoplasmic reticulum lumen,peptide lysine modification and other pathways.Conclusion:The expression of miR-29a-3p in NSCLC was significantly low,and miR-29a-3p can inhibit the proliferation and migration of NSCLC cells.
作者
朱俊
姜云
徐莹莹
刘剑
ZHU Jun;JIANG Yun;XU Yingying;LIU Jian(Department of Cardiothoracic Surgery,Affiliated Hospital of Nantong University,Jiangsu 226001;Department of Oncology and chemotherapy,Affiliated Hospital of Nantong University,Jiangsu 226001)
出处
《交通医学》
2023年第1期28-32,共5页
Medical Journal of Communications